行情

SRRA

SRRA

SIERRA ONCOLOGY
NASDAQ

实时行情|Nasdaq Last Sale

0.4547
-0.0002
-0.03%
已收盘, 16:00 09/17 EDT
开盘
0.4550
昨收
0.4549
最高
0.4550
最低
0.4450
成交量
13.05万
成交额
--
52周最高
2.010
52周最低
0.4000
市值
2,385.09万
市盈率(TTM)
-0.5863
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SRRA 新闻

  • 韩国出牌正式将日本踢出白名单 “战火”跨界延烧
  • 中国新闻网.3小时前
  • 特朗普提名的理事人选谢尔顿呼吁美联储与白宫合作
  • 新浪财经综合.3小时前
  • 沪指小幅高开 美联储十年来首次重启回购操作
  • 新浪财经.3小时前
  • 内部有分歧的美联储本周势将再度降息 但之后呢?
  • 新浪财经综合.4小时前

更多

所属板块

生物技术和医学研究
+0.24%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

SRRA 简况

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
展开

Webull提供Sierra Oncology Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。